A biomarker that has proven to be a predictor for response to immunotherapies in melanoma patients also has clinical relevance for breast cancer patients, according to a new study published in Clinical Cancer Research, a journal of the American Association for Cancer Research.
Immune checkpoint inhibitors — cancer therapies that remove the “brakes” on the adaptive anti-tumor immune response — have had remarkable success in melanoma and lung cancer.
October 1, 2013, Avon Foundation for Women, in partnership with the National Cancer Institute and the Center for Advancing Innovation, kicked off a nationwide start-up challenge.
